Asset
IPH-2101
Revenue
No revenue reported in loaded filings.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01256073 | phase1 | completed | 2007-02-01 | 2013-07-01 | Innate Pharma | A Safety and Tolerability Extension Trial Assessing Repeated Dosing of Anti-KIR (1-7F9) Human Monoclonal Antibody in Patients With Acute Myeloid Leukaemia |
| NCT00999830 | phase2 | completed | 2009-09-01 | 2012-06-01 | Innate Pharma | Evaluation of Activity, Safety and Pharmacology of IPH2101 a Human Monoclonal Antibody in Patients With Multiple Myeloma |
| NCT01222286 | phase2 | completed | 2010-09-01 | 2012-07-01 | Innate Pharma | Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma |
FDA applications (0)
This company has no applications containing this asset.